Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701)
详细信息 查看全文
- 作者：Shigefumi Yoshinoa ; sigefumi@yamaguchi-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Kazuhiro Nishikawab ; 1 ; Satoshi Moritac ; Tsuyoshi Takahashid ; Koichiro Sakatae ; Jiro Nagaof ; Hiroshi Nemotog ; Nozomu Murakamih ; Takeru Matsudai ; Hiroyasu Hasegawaj ; Ryoichi Shimizuk ; Takaki Yoshikawal ; Hiroyuki Osanaim ; Motohiro Imanon ; Hiroshi Naitoho ; Akiyoshi Tanakap ; Takashi Tajiriq ; Akira Gochir ; Michinari Suzukis ; Junichi Sakamotot ; Shigetoyo Sajit ; Masaaki Okau
- 关键词：Lentinan ; S-1 ; Gastric cancer ; Quality of life ; Biomarker ; Phase III study
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：65
- 期：Complete
- 页码：164-171
- 全文大小：750 K
文摘
- •
Lentinan (LNT) is a purified β-1, 3-glucan and augments immune responses.
- •
A phase III study of S-1 versus S-1 plus LNT was conducted for advanced gastric cancer.
- •
This study showed no efficacy of LNT combined with S-1 treatment.
- •
LNT-binding monocytes were analysed for the biomarker assessment.
- •
In S-1 plus LNT group, long survivors were seen in subgroup of patients with a high percentage of LNT-binding monocytes.